| Name | Title | Contact Details |
|---|
Revolutionary Products for Soft Tissue Replacement and Regeneration
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body`s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders.
Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company`s platform represents a potentially fundamental shift in what`s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.
Kythera Biopharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.